| Document |
Document Title |
|
WO/2024/091882A1 |
This patent document discloses novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the comp...
|
|
WO/2024/089421A1 |
The invention relates to compounds of formula (I) and related aspects.
|
|
WO/2024/083099A1 |
Disclosed in the present invention are a drug intermediate and a preparation method therefor, and specifically disclosed are a compound as represented by formula (I) and a preparation method therefor.
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/074126A1 |
Provided are a 4-methylsulfonylbenzamide compound having a structure represented by general formula (I) and having a sulfur-containing substituent at position 3, a stereoisomer thereof, an agriculturally acceptable salt thereof, a prepar...
|
|
WO/2024/074648A1 |
The present invention relates to a method for precipitating the gadolinium complex of formula (I) from a solution comprising such gadolinium complex by means of mixing a first solution comprising the complex with a second solution, as we...
|
|
WO/2024/067784A1 |
Provided are an amorphous form and 16 crystal forms of a compound represented by formula (I). The crystal forms are named in order from crystal form A to crystal form P. Also provided is a preparation method for the amorphous form and po...
|
|
WO/2024/073155A1 |
A composition comprising a hydrogel includes a polymer of formula (1), at least one repeating unit of which comprises norbomene. Methods of treating wounds and methods of encapsulating drugs and/or cells using such hydrogels are also dis...
|
|
WO/2024/052549A1 |
The present invention relates to a new class of compounds of general formula (I), to the metal chelates with a metal ion suitable for computed tomography thereof, to the Gd3+ chelate complexes thereof, to methods of preparing said compou...
|
|
WO/2024/044552A1 |
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...
|
|
WO/2024/044549A1 |
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...
|
|
WO/2024/034686A1 |
The present invention provides a polymer contrast agent. The present invention relates to a copolymer in which a chelating agent molecule is bonded to a copolymer X constituted of structural units represented by formulae (A), (B) and (...
|
|
WO/2024/035831A1 |
Tetrazolium-based compounds are described herein that are capable of undergoing reduction reactions under physiological conditions after crossing over the cell membrane. Reduction of the tetrazolium-based compounds results in ring-openin...
|
|
WO/2024/036100A1 |
Disclosed are compounds of Formula (I): or a salt thereof, wherein: X, Y, Z, R1, R2, R3, and n are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (...
|
|
WO/2024/028169A1 |
The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory acti...
|
|
WO/2024/030772A1 |
A compound has a structure according to formula IA or IB, or a salt or stereoisomer thereof: (IA) or (IB), where each R1 independently is an aryl or aliphatic group having an sp2‑hybridized or sp‑hybridized carbon at its attachment p...
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2022/241470A9 |
Disclosed herein are methods of molecular magnetic resonance (MR) imaging and positron emission tomography using extracellular probes that target extracellular allysine aldehyde and act as a noninvasive biomarker of fibrogenesis with hig...
|
|
WO/2024/023332A1 |
The invention relates to novel silicon-based fluoride acceptor groups (SiFA groups) of the following formulae (Ia, Ib, Ic) as well as to compounds suitable for use in radiopharmacy comprising such groups, wherein R1 and R2 are each a lin...
|
|
WO/2024/020350A1 |
The present disclosure provides, in part, compounds of formula (I): wherein the variables are as defined herein, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat physiological disorders, s...
|
|
WO/2024/017762A1 |
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to me...
|
|
WO/2024/011414A1 |
Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...
|
|
WO/2024/013058A1 |
The present invention describes salts of SCO-101, crystals and amorphs thereof, as well as pharmaceutical compositions comprising the salts, methods for making them, and their use in treatment of cancer.
|
|
WO/2023/237015A1 |
The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl...
|
|
WO/2023/239104A1 |
The present invention relates to a method for preparing dihydroxyammonium 5,5'-bistetrazole-1,1'-diolate. The method for preparing dihydroxyammonium 5,5'-bistetrazole-1,1'-diolate, according to one embodiment of the present invention, co...
|
|
WO/2023/229859A1 |
During the production of Hexahydro-1, 3, 5-trinitro-l, 3, 5-triazine and Octahydro-1,3, 5, 7-tetranitro-l, 3,5, 7-tetrazocine via the Bachmann nitrolysis process, it is necessary to recover the entire mass of acetic acid and restore it t...
|
|
WO/2023/220836A1 |
The present disclosure relates generally to new bifunctional linchpins that react selectively with cysteine residues to invoke cyclization while concurrently introducing a radiometal chelation ligand or silicon-based fluoride acceptor (S...
|
|
WO/2023/222681A1 |
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate can...
|
|
WO/2023/210510A1 |
Provided is a method for producing a radioactive metal complex comprising a complex forming step for causing a radioactive metal nuclide and a ligand compound represented by formula (1) to react with each other in a reaction solution con...
|
|
WO/2023/211412A1 |
The present invention relates to a film coated tablet comprising intragranular composition comprising sacubitril sodium, valsartan disodium and an extragranular composition, wherein the tablet is obtained by dry granulation.
|
|
WO/2023/209090A1 |
The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in th...
|
|
WO/2023/201374A1 |
The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, pro...
|
|
WO/2023/201377A2 |
The present disclosure provides compounds and methods for "scission-enhanced" nuclear imaging and treatment ("SENIT"). In one example, the disclosure provides a conjugate where an affinity ligand (e.g., an antibody) is connected to a rad...
|
|
WO/2023/196538A1 |
Substituted benzofuran, benzothiophene, and indole carboxamide compounds, conjugates, and pharmaceutical compositions for use as immunotherapeutics in the treatment of cancer, such as solid tumors, are disclosed herein. The disclosed com...
|
|
WO/2023/190402A1 |
Provided is a method for producing a complex of a radioactive metal nuclear species and an antibody, the method comprising a step for reacting a radioactive metal nuclear species with an antibody modified with a coordination compound in ...
|
|
WO/2023/180688A1 |
The following invention relates to methods of producing explosives from the nitration of TAT by flow synthesis. The invention relates to a method for the flow synthesis manufacture of HMX, (1,3,5,7-tetranitro-1,3,5,7-tetraazacyclooctane)...
|
|
WO/2023/173618A1 |
The present invention provides a cyclic Gd(III) complex, which has a chemical structure as shown in formula I, wherein a ring structure of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, namely DOTA, is used as a parent ring, l...
|
|
WO/2023/170164A1 |
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with comp...
|
|
WO/2023/170174A1 |
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with comp...
|
|
WO/2023/172112A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising the compound.
|
|
WO/2023/166511A1 |
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
|
|
WO/2023/164775A1 |
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1 is –R1aR1b– wherein R1a is absent, –CH2–, –O–, or –S–, and R1b is –CH...
|
|
WO/2022/085570A9 |
The present invention pertains to a method that is for producing a radioactive zirconium labelled complex and that can achieve a high labelling rate in a reaction between a ligand compound and radioactive zirconium ions. The production m...
|
|
WO/2023/158795A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/152711A1 |
The present invention relates to a process for the preparation of Cenobamate and intermediates thereof.
|
|
WO/2023/148748A1 |
Disclosed herein is an improved, safe and novel method for the elimination of nitrosamine impurities during the preparation of sartan class of drugs containing tetrazole ring structure represented by general formula I, more particularly ...
|
|
WO/2023/143612A1 |
Disclosed are a peptide urea derivative, a pharmaceutical composition containing the peptide urea derivative, and an application of the peptide urea derivative. The derivative is as represented by formula I, wherein R is a group containi...
|
|
WO/2023/143354A1 |
The present invention relates to a tricyclic compound represented by formula (O), a pharmaceutical composition comprising the compound as an active ingredient, and an application thereof. The compound is an excellent TEAD inhibitor and c...
|
|
WO/2023/122588A2 |
Compounds, e.g., radioimmunoconjugates, including a chelating moiety or a metal complex thereof, a linker, and an antibody or antigen-binding fragment thereof targeting both EGFR and cMET. Pharmaceutical compositions of such compounds an...
|
|
WO/2023/121753A1 |
The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, ...
|
